These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38110354)

  • 1. Inhibition of LRRK2 kinase activity rescues deficits in striatal dopamine physiology in VPS35 p.D620N knock-in mice.
    Bu M; Follett J; Deng I; Tatarnikov I; Wall S; Guenther D; Maczis M; Wimsatt G; Milnerwood A; Moehle MS; Khoshbouei H; Farrer MJ
    NPJ Parkinsons Dis; 2023 Dec; 9(1):167. PubMed ID: 38110354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition.
    Kadgien CA; Kamesh A; Milnerwood AJ
    Mol Brain; 2021 Sep; 14(1):143. PubMed ID: 34530877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered dopamine release and monoamine transporters in Vps35 p.D620N knock-in mice.
    Cataldi S; Follett J; Fox JD; Tatarnikov I; Kadgien C; Gustavsson EK; Khinda J; Milnerwood AJ; Farrer MJ
    NPJ Parkinsons Dis; 2018; 4():27. PubMed ID: 30155515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes.
    Wang X; Bondar VV; Davis OB; Maloney MT; Agam M; Chin MY; Cheuk-Nga Ho A; Ghosh R; Leto DE; Joy D; Calvert MEK; Lewcock JW; Di Paolo G; Thorne RG; Sweeney ZK; Henry AG
    Elife; 2023 Oct; 12():. PubMed ID: 37874617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity.
    Kalogeropulou AF; Freemantle JB; Lis P; Vides EG; Polinski NK; Alessi DR
    Biochem J; 2020 Nov; 477(22):4397-4423. PubMed ID: 33135724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired neurogenesis in the hippocampus of an adult VPS35 mutant mouse model of Parkinson's disease through interaction with APP.
    Jiang M; Tu HT; Zhang K; Zhang W; Yu WP; Xu J; Tan EK; Guo KH; Zeng L
    Neurobiol Dis; 2021 Jun; 153():105313. PubMed ID: 33636388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered striatal dopamine levels in Parkinson's disease VPS35 D620N mutant transgenic aged mice.
    Vanan S; Zeng X; Chia SY; Varnäs K; Jiang M; Zhang K; Saw WT; Padmanabhan P; Yu WP; Zhou ZD; Halldin C; Gulyás B; Tan EK; Zeng L
    Mol Brain; 2020 Dec; 13(1):164. PubMed ID: 33261640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of
    Sargent D; Moore DJ
    Int Rev Mov Disord; 2021; 2():221-244. PubMed ID: 35497708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired striatal dopamine release in homozygous Vps35 D620N knock-in mice.
    Ishizu N; Yui D; Hebisawa A; Aizawa H; Cui W; Fujita Y; Hashimoto K; Ajioka I; Mizusawa H; Yokota T; Watase K
    Hum Mol Genet; 2016 Oct; 25(20):4507-4517. PubMed ID: 28173004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Parkinson's disease related mutant VPS35 (D620N) amplifies the LRRK2 response to endolysosomal stress.
    McCarron KR; Elcocks H; Mortiboys H; Urbé S; Clague MJ
    Biochem J; 2024 Feb; 481(4):265-278. PubMed ID: 38299383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VPS35 D620N knockin mice recapitulate cardinal features of Parkinson's disease.
    Niu M; Zhao F; Bondelid K; Siedlak SL; Torres S; Fujioka H; Wang W; Liu J; Zhu X
    Aging Cell; 2021 May; 20(5):e13347. PubMed ID: 33745227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's VPS35[D620N] mutation induces LRRK2-mediated lysosomal association of RILPL1 and TMEM55B.
    Pal P; Taylor M; Lam PY; Tonelli F; Hecht CA; Lis P; Nirujogi RS; Phung TK; Yeshaw WM; Jaimon E; Fasimoye R; Dickie EA; Wightman M; Macartney T; Pfeffer SR; Alessi DR
    Sci Adv; 2023 Dec; 9(50):eadj1205. PubMed ID: 38091401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant VPS35-D620N induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway.
    Huang Y; Huang H; Zhou L; Li J; Chen X; Thomas J; He X; Guo W; Zeng Y; Low BC; Liang F; Zeng J; Ross CA; Tan EK; Smith W; Pei Z
    Hum Mol Genet; 2022 Nov; 31(22):3886-3896. PubMed ID: 35766879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VPS35 and retromer dysfunction in Parkinson's disease.
    Rowlands J; Moore DJ
    Philos Trans R Soc Lond B Biol Sci; 2024 Apr; 379(1899):20220384. PubMed ID: 38368930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes.
    Mercatelli D; Bolognesi P; Frassineti M; Pisanò CA; Longo F; Shimshek DR; Morari M
    Pharmacol Res Perspect; 2019 Jun; 7(3):e00484. PubMed ID: 31149340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson's disease mutant of Leucine-Rich Repeat Kinase 2 (LRRK2).
    Linhart R; Wong SA; Cao J; Tran M; Huynh A; Ardrey C; Park JM; Hsu C; Taha S; Peterson R; Shea S; Kurian J; Venderova K
    Mol Neurodegener; 2014 Jun; 9():23. PubMed ID: 24915984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N.
    Munsie LN; Milnerwood AJ; Seibler P; Beccano-Kelly DA; Tatarnikov I; Khinda J; Volta M; Kadgien C; Cao LP; Tapia L; Klein C; Farrer MJ
    Hum Mol Genet; 2015 Mar; 24(6):1691-703. PubMed ID: 25416282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 and the Endolysosomal System in Parkinson's Disease.
    Erb ML; Moore DJ
    J Parkinsons Dis; 2020; 10(4):1271-1291. PubMed ID: 33044192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.